Comparison of Zotarolimus- and Everolimus-Eluting Coronary Stents Final 5-Year Report of the RESOLUTE All-Comers Trial
| Autor: | Manuela Negoita, Javaid Iqbal, Henning Kelbæk, Gert Richardt, Paweł Buszman, Patrick W. Serruys, Sigmund Silber, Marie-Angèle Morel, Stephan Windecker |
|---|---|
| Přispěvatelé: | Cardiology |
| Rok vydání: | 2015 |
| Předmět: |
Male
Cardiac & Cardiovascular Systems BALLOON ANGIOPLASTY medicine.medical_treatment Clinical endpoint Medicine ARTERY-DISEASE Myocardial infarction 610 Medicine & health BARE-METAL STENTS education.field_of_study Drug-Eluting Stents Middle Aged ANGIOGRAPHIC OUTCOMES TWENTE TRIAL Treatment Outcome Drug-eluting stent Cardiology Female Cardiology and Cardiovascular Medicine Life Sciences & Biomedicine medicine.drug medicine.medical_specialty XIENCE V STENTS CLINICAL-OUTCOMES Population Antineoplastic Agents percutaneous coronary interventions Percutaneous Coronary Intervention Internal medicine drug-eluting stent Humans Zotarolimus Everolimus education REAL-WORLD PATIENTS Aged Sirolimus Science & Technology ANTIPLATELET THERAPY business.industry Stent Percutaneous coronary intervention medicine.disease Surgery Cardiovascular System & Hematology zotarolimus Cardiovascular System & Cardiology business FOLLOW-UP Follow-Up Studies |
| Zdroj: | Circulation-cardiovascular interventions, 8(6). Lippincott Williams & Wilkins Iqbal, Javaid; Serruys, Patrick W; Silber, Sigmund; Kelbaek, Henning; Richardt, Gert; Morel, Marie-Angele; Negoita, Manuela; Buszman, Pawel E; Windecker, Stephan (2015). Comparison of zotarolimus-and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circulation: Cardiovascular interventions, 8(6), e002230. Lippincott Williams & Wilkins 10.1161/CIRCINTERVENTIONS.114.002230 |
| ISSN: | 1941-7640 |
| DOI: | 10.1161/CIRCINTERVENTIONS.114.002230 |
| Popis: | Background— Newer-generation drug-eluting stents that release zotarolimus or everolimus have been shown to be superior to the first-generation drug-eluting stents. However, data comparing long-term safety and efficacy of zotarolimus- (ZES) and everolimus-eluting stents (EES) are limited. RESOLUTE all-comers (Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention) trial compared these 2 stents and has shown that ZES was noninferior to EES at 12-month for the primary end point of target lesion failure. We report the secondary clinical outcomes at the final 5-year follow-up of this trial. Methods and Results— RESOLUTE all-comer clinical study is a prospective, multicentre, randomized, 2-arm, open-label, noninferiority trial with minimal exclusion criteria. Patients (n=2292) were randomly assigned to treatment with either ZES (n=1140) or EES (n=1152). Patient-oriented composite end point (combination of all-cause mortality, myocardial infarction, and any revascularizations), device-oriented composite end point (combination of cardiac death, target vessel myocardial infarction, and clinically indicated target lesion revascularization), and major adverse cardiac events (combination of all-cause death, all myocardial infarction, emergent coronary bypass surgery, or clinically indicated target lesion revascularization) were analyzed at 5-year follow-up. The 2 groups were well-matched at baseline. Five-year follow-up data were available for 98% patients. There were no differences in patient-oriented composite end point (ZES 35.3% versus EES 32.0%, P =0.11), device-oriented composite end point (ZES 17.0% versus EES 16.2%, P =0.61), major adverse cardiac events (ZES 21.9% versus EES 21.6%, P =0.88), and definite/probable stent thrombosis (ZES 2.8% versus EES 1.8%, P =0.12). Conclusions— At 5-year follow-up, ZES and EES had similar efficacy and safety in a population of patients who had minimal exclusion criteria. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00617084. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|